Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Increased schizophrenia family history burden and reduced premorbid IQ in treatment-resistant schizophrenia: a Swedish National Register and Genomic Study

Molecular Psychiatry volume 26, pages 4487–4495 (2021)Cite this article

Subjects

Abstract

A high proportion of those with schizophrenia experience treatment non-response, placing them at higher risk for mortality and suicide attempts, compared to treatment responders. The clinical, social, and economic burden of treatment-resistant schizophrenia (TRS) are substantial. Previous genomic and epidemiological studies of TRS were often limited by sample size or lack of comprehensive genomic data. We aimed to systematically understand the clinical, demographic, and genomic correlates of TRS using epidemiological and genetic epidemiological modelling in a Swedish national population sample (n = 24,706) and then in a subgroup with common variant genetic risk scores, rare copy-number variant burden, and rare exonic burden (n = 4936). Population-based analyses identified increasing schizophrenia family history to be significantly associated with TRS (highest quartile of familial burden vs. lowest: adjusted odds ratio (aOR): 1.31, P = 4.8 × 10-8). In males, a decrease of premorbid IQ of one standard deviation was significantly associated with greater risk of TRS (minimal aOR: 0.94, P = 0.002). In a subset of cases with extensive genomic data, we found no significant association between the genetic risk scores of four psychiatric disorders and two cognitive traits with TRS (schizophrenia genetic risk score: aOR = 1.07, P = 0.067). The association between copy number variant and rare variant burden measures and TRS did not reach the pre-defined statistical significance threshold (all P ≥ 0.005). In conclusion, direct measures of genomic risk were not associated with TRS; however, premorbid IQ in males and schizophrenia family history were significantly correlated with TRS and points to new insights into the architecture of TRS.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Fig. 1
Fig. 2
Fig. 3

Code availability

Custom written R scripts used for statistical analyses can be provided upon request.

References

  1. Barnes T. Schizophrenia Consensus Group of British Association for Psychopharmacology. Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2011;25:567–620.

    CAS  PubMed  Google Scholar 

  2. Wimberley T, MacCabe JH, Laursen TM, Sørensen HJ, Astrup A, Horsdal HT, et al. Mortality and self-harm in association with clozapine in treatment-resistant schizophrenia. Am J Psychiatry. 2017;174:990–8.

    PubMed  Google Scholar 

  3. Wimberley T, Stovring H, Sorensen HJ, Horsdal HT, MacCabe JH, Gasse C, et al. Predictors of treatment resistance in patients with schizophrenia: A population-based cohort study. Lancet Psychiatry. 2016;3:358–66.

    PubMed  Google Scholar 

  4. Kennedy JL, Altar CA, Taylor DL, Degtiar I, Hornberger JC. The social and economic burden of treatment-resistant schizophrenia: a systematic literature review. Int Clin Psychopharmacol. 2014;29:63–76.

    PubMed  Google Scholar 

  5. de Bartolomeis A, Balletta R, Giordano S, Buonaguro EF, Latte G, Iasevoli F. Differential cognitive performances between schizophrenic responders and non-responders to antipsychotics: correlation with course of the illness, psychopathology, attitude to the treatment and antipsychotics doses. Psychiatry Res. 2013;210:387–95.

    PubMed  Google Scholar 

  6. Frydecka D, Beszłej JA, Gościmski P, Kiejna A, Misiak B. Profiling cognitive impairment in treatment-resistant schizophrenia patients. Psychiatry Res. 2016;235:133–8.

    PubMed  Google Scholar 

  7. Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry. 1988;45:789–96.

    CAS  PubMed  Google Scholar 

  8. Suzuki T, Remington G, Mulsant BH, Rajji TK, Uchida H, Graff-Guerrero A, et al. Treatment resistant schizophrenia and response to antipsychotics: A review. Schizophr Res. 2011;133:54–62.

    PubMed  Google Scholar 

  9. Bachmann CJ, Aagaard L, Bernardo M, Brandt L, Cartabia M, Clavenna A, et al. International trends in clozapine use: a study in 17 countries. Acta Psychiatr Scand. 2017;136:37–51.

    CAS  PubMed  Google Scholar 

  10. Crespo-Facorro B, de la Foz VOG, Ayesa-Arriola R, Pérez-Iglesias R, Mata I, Suarez-Pinilla P, et al. Prediction of acute clinical response following a first episode of non affective psychosis: Results of a cohort of 375 patients from the Spanish PAFIP study. Prog Neuro-Psychopharmacol Biol Psychiatry. 2013;44:162–7.

    Google Scholar 

  11. Hassan AN, De Luca V. The effect of lifetime adversities on resistance to antipsychotic treatment in schizophrenia patients. Schizophr Res. 2015;161:496–500.

    PubMed  Google Scholar 

  12. Frank J, Lang M, Witt SH, Strohmaier J, Rujescu D, Cichon S, et al. Identification of increased genetic risk scores for schizophrenia in treatment-resistant patients. Mol Psychiatry. 2015;20:150–1.

    CAS  PubMed  Google Scholar 

  13. Martin AK, Mowry B. Increased rare duplication burden genomewide in patients with treatment-resistant schizophrenia. Psychol Med. 2016;46:469–76.

    CAS  PubMed  Google Scholar 

  14. Horsdal HT, Meier SM, Wimberley T, Agerbo E, Gasse C, MacCabe JH. Polygenic risk score for schizophrenia and treatment-resistant schizophrenia. Schizophr Bull. 2017;43:1064–9.

    PubMed  PubMed Central  Google Scholar 

  15. Zhang JP, Robinson D, Yu J, Gallego J, Fleischhacker WW, Kahn RS, et al. Schizophrenia polygenic risk score as a predictor of antipsychotic efficacy in first-episode psychosis. Am J Psychiatry. 2019;176:21–8.

    PubMed  Google Scholar 

  16. Lee SH, DeCandia TR, Ripke S, Yang J. Schizophrenia Psychiatric Genome-Wide Association Study Consortium (PGC-SCZ) PF, International Schizophrenia Consortium (ISC) ME, et al. Estimating the proportion of variation in susceptibility to schizophrenia captured by common SNPs. Nat Genet. 2012;44:247–50.

    CAS  PubMed  PubMed Central  Google Scholar 

  17. Ruderfer DM, Charney AW, Readhead B, Kidd BA, Kähler AK, Kenny PJ, et al. Polygenic overlap between schizophrenia risk and antipsychotic response: A genomic medicine approach. Lancet Psychiatry. 2016;3:350–7.

    PubMed  PubMed Central  Google Scholar 

  18. Wang Q, Man WuH, Yue W, Yan H, Zhang Y, Tan L, et al. Effect of damaging rare mutations in synapse-related gene sets on response to short-term antipsychotic medication in chinese patients with schizophrenia. JAMA Psychiatry. 2018;75:1261.

    PubMed  PubMed Central  Google Scholar 

  19. Jedenius E, Tanskanen A, Leval A, Hoti F, Majak M, Taipale H, et al. Real-world effectiveness of antipsychotic treatments in a nationwide cohort of 29 823 patients with schizophrenia. JAMA Psychiatry. 2017;74:686.

    PubMed  PubMed Central  Google Scholar 

  20. Wettermark B, Hammar N, Fored CM, Leimanis A, Olausson PO, Bergman U, et al. The new Swedish Prescribed Drug Register Opportunities for pharmacoepidemiological research and experience from the first six months. Pharmacoepidemiol Drug Saf. 2007;16:726–35.

    PubMed  Google Scholar 

  21. Ripke S, O’Dushlaine C, Chambert K, Moran JL, Kahler AK, Akterin S, et al. Genome-wide association analysis identifies 13 new risk loci for schizophrenia. Nat Genet. 2013;45:1150–9.

    CAS  PubMed  PubMed Central  Google Scholar 

  22. Ludvigsson JF, Andersson E, Ekbom A, Feychting M, Kim JL, Reuterwall C, et al. External review and validation of the Swedish national inpatient register. BMC Public Health. 2011;11:450.

    PubMed  PubMed Central  Google Scholar 

  23. Ekbom A. The Swedish Multi-generation Register. Methods Mol Biol. 2010;675:215–20.

    Google Scholar 

  24. Brooke HL, Talbäck M, Hörnblad J, Johansson LA, Ludvigsson JF, Druid H, et al. The Swedish cause of death register. Eur J Epidemiol. 2017;32:765–73.

    CAS  PubMed  PubMed Central  Google Scholar 

  25. Ajnakina O, Horsdal HT, Lally J, MacCabe JH, Murray RM, Gasse C, et al. Validation of an algorithm-based definition of treatment resistance in patients with schizophrenia. Schizophr Res. 2018;197:294–7.

    PubMed  Google Scholar 

  26. Sullivan PF, Wells JE, Joyce PR, Bushnell JA, Mulder RT, Oakley-Browne MA. Family history of depression in clinic and community samples. J Affect Disord. 1996;40:159–68.

    CAS  PubMed  Google Scholar 

  27. Purcell SM, Wray NR, Stone JL, Visscher PM, O’Donovan MC, Sullivan PF, et al. Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature. 2009;10:8192–92.

    Google Scholar 

  28. Ripke S, Neale BM, Corvin A, Walters JTR, Farh KH, Holmans PA, et al. Biological insights from 108 schizophrenia-associated genetic loci. Nature. 2014;511:421–7.

    CAS  PubMed Central  Google Scholar 

  29. Cross-Disorder Group of the Psychiatric Genomics Consortium. Identification of the Psychiatric Genomics Consortium. Identification of risk loci with shared effects on five major psychiatric disorders: a genome-wide analysis. Lancet (Lond, Engl). 2013;381:1371–9.

    Google Scholar 

  30. Hubbard L, Tansey KE, Rai D, Jones P, Ripke S, Chambert KD, et al. Evidence of common genetic overlap between schizophrenia and cognition. Schizophr Bull. 2016;42:832–42.

    PubMed  Google Scholar 

  31. Leeson VC, Barnes TRE, Hutton SB, Ron MA, Joyce EM. IQ as a predictor of functional outcome in schizophrenia: a longitudinal, four-year study of first-episode psychosis. Schizophr Res. 2009;107:55–60.

    PubMed  PubMed Central  Google Scholar 

  32. van Winkel R, Myin-Germeys I, De Hert M, Delespaul P, Peuskens J, van Os J. The association between cognition and functional outcome in first-episode patients with schizophrenia: mystery resolved? Acta Psychiatr Scand. 2007;116:119–24.

    PubMed  Google Scholar 

  33. Escott-Price V, Bracher-Smith M, Menzies G, Walters J, Kirov G, Owen MJ, et al. Genetic liability to schizophrenia is negatively associated with educational attainment in UK Biobank. Mol Psychiatry. 2019; https://doi.org/10.1038/s41380-018-0328-6.

  34. Hagenaars SP, Harris SE, Davies G, Hill WD, Liewald DCM, Ritchie SJ, et al. Shared genetic aetiology between cognitive functions and physical and mental health in UK Biobank (N=112151) and 24 GWAS consortia. Mol Psychiatry. 2016;21:1624–32.

    CAS  PubMed  PubMed Central  Google Scholar 

  35. Wray NR, Ripke S, Mattheisen M, Trzaskowski M, Byrne EM, Abdellaoui A, et al. Genome-wide association analyses identify 44 risk variants and refine the genetic architecture of major depression. Nat Genet. 2018;50:668–81.

    CAS  PubMed  PubMed Central  Google Scholar 

  36. Green EK, Hamshere M, Forty L, Gordon-Smith K, Fraser C, Russell E, et al. Replication of bipolar disorder susceptibility alleles and identification of two novel genome-wide significant associations in a new bipolar disorder case-control sample. Mol Psychiatry. 2013;18:1302–7.

    CAS  PubMed  Google Scholar 

  37. Autism Spectrum Disorders Working Group of The Psychiatric Genomics Consortium. Meta-analysis of GWAS of over 16,000 individuals with autism spectrum disorder highlights a novel locus at 10q24.32 and a significant overlap with schizophrenia. Mol Autism. 2017;8:21.

    Google Scholar 

  38. Lee JJ, Wedow R, Okbay A, Kong E, Maghzian O, Zacher M, et al. Gene discovery and polygenic prediction from a genome-wide association study of educational attainment in 1.1 million individuals. Nat Genet. 2018;50:1112–21.

    CAS  PubMed  PubMed Central  Google Scholar 

  39. Savage JE, Jansen PR, Stringer S, Watanabe K, Bryois J, De Leeuw CA, et al. Genome-wide association meta-analysis in 269,867 individuals identifies new genetic and functional links to intelligence. Nat Genet. 2018;50:912–9.

    CAS  PubMed  PubMed Central  Google Scholar 

  40. Szatkiewicz JP, O’Dushlaine C, Chen G, Chambert K, Moran JL, Neale BM, et al. Copy number variation in schizophrenia in Sweden. Mol Psychiatry. 2014;19:762–73.

    CAS  PubMed  PubMed Central  Google Scholar 

  41. Tansey KE, Rees E, Linden DE, Ripke S, Chambert KD, Moran JL, et al. Common alleles contribute to schizophrenia in CNV carriers. Mol Psychiatry. 2016;21:1085–9.

    CAS  PubMed  Google Scholar 

  42. Genovese G, Fromer M, Stahl EA, Ruderfer DM, Chambert K, Landen M, et al. Increased burden of ultra-rare protein-altering variants among 4,877 individuals with schizophrenia. Nat Neurosci. 2016;19:1433–41.

    CAS  PubMed  PubMed Central  Google Scholar 

  43. Purcell SM, Moran JL, Fromer M, Ruderfer D, Solovieff N, Roussos P, et al. A polygenic burden of rare disruptive mutations in schizophrenia. Nature. 2014;506:185–90.

    CAS  PubMed  PubMed Central  Google Scholar 

  44. Lek M, Karczewski KJ, Minikel EV, Samocha KE, Banks E, Fennell T, et al. Analysis of protein-coding genetic variation in 60,706 humans. Nature. 2016;536:285–91.

    CAS  PubMed  PubMed Central  Google Scholar 

  45. Ioannidis JPA. The proposal to lower P value thresholds to .005. JAMA. 2018;319:1429–30.

    PubMed  Google Scholar 

  46. Sumiyoshi C, Fujino H, Yamamori H, Kudo N, Azechi H, Fujimoto M, et al. Predicting work outcome in patients with schizophrenia: Influence of IQ decline. Schizophr Res. 2018;201:172–9.

    PubMed  Google Scholar 

  47. Barnett JH, Salmond CH, Jones PB, Sahakian BJ. Cognitive reserve in neuropsychiatry. Psychol Med. 2006;36:1053–64.

    CAS  PubMed  Google Scholar 

  48. Mortensen PB, Pedersen CB, Westergaard T, Wohlfahrt J, Ewald H, Mors O, et al. Effects of family history and place and season of birth on the risk of schizophrenia. N Engl J Med. 1999;340:603–8.

    CAS  PubMed  Google Scholar 

  49. Murray RM, Van OsJ. Predictors of outcome in schizophrenia. J Clin Psychopharmacol. 1998;18:2S–4S.

    CAS  PubMed  Google Scholar 

  50. Hunt SC, Williams RR, Barlow GK. A comparison of positive family history definitions for defining risk of future disease. J Chronic Dis. 1986;39:809–21.

    CAS  PubMed  Google Scholar 

  51. McCutcheon R, Beck K, D’Ambrosio E, Donocik J, Gobjila C, Jauhar S, et al. Antipsychotic plasma levels in the assessment of poor treatment response in schizophrenia. Acta Psychiatr Scand. 2018;137:39–46.

    CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This work was supported by the Swedish Research Council (Vetenskapsrådet, award D0886501 to PFS). The Sweden Schizophrenia Study was supported by NIMH R01 MH077139. KK received funding from the European Union’s Horizon 2020 Research and Innovation programme under the Marie Skłodowska-Curie grant agreement (No. 793530) and from the Government of Canada Banting Postdoctoral Fellowship Programme.

Author information

Authors and Affiliations

  1. Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden

    Kaarina Kowalec, Yi Lu, Amir Sariaslan, Jie Song, Alexander Ploner, Christina M. Hultman, Henrik Larsson, Paul Lichtenstein & Patrick F. Sullivan

  2. College of Pharmacy, University of Manitoba, Winnipeg, MB, Canada

    Kaarina Kowalec

  3. Department of Public Health Sciences, Karolinska Institutet, Stockholm, Sweden

    Christina Dalman

  4. Icahn School of Medicine, Department of Psychiatry, Mt. Sinai Hospital, New York, NY, USA

    Christina M. Hultman

  5. School of Medical Sciences, Örebo University, Örebo, Sweden

    Henrik Larsson

  6. Departments of Genetics and Psychiatry, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

    Patrick F. Sullivan

Authors
  1. Kaarina Kowalec
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yi Lu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Amir Sariaslan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jie Song
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Alexander Ploner
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Christina Dalman
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Christina M. Hultman
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Henrik Larsson
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Paul Lichtenstein
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Patrick F. Sullivan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Patrick F. Sullivan.

Ethics declarations

Conflict of interest

PFS reports the following potential competing financial interests: Current: Lundbeck (advisory committee, grant recipient); Past 3 years: Pfizer (scientific advisory board), Element Genomics (consultation fee), and Roche (speaker reimbursement). HL has served as a speaker for Evolan Pharma and Shire, and has received research grants from Shire; all outside the submitted work. All other authors report no disclosures related to this work.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Reprints and Permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kowalec, K., Lu, Y., Sariaslan, A. et al. Increased schizophrenia family history burden and reduced premorbid IQ in treatment-resistant schizophrenia: a Swedish National Register and Genomic Study. Mol Psychiatry 26, 4487–4495 (2021). https://doi.org/10.1038/s41380-019-0575-1

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41380-019-0575-1

This article is cited by

Search

Advanced search

Quick links